Liver cholesterol: Is it playing possum in NASH?

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 303, Issue 1, 2012, Pages

  Farrell, Geoffrey C ^a   van Rooyen, Derrick ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCB4 PROTEIN; CD36 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CHOLESTEROL LIVER LEVEL; EDITORIAL; GENE EXPRESSION; GENETIC PREDISPOSITION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOADIPONECTINEMIA; LIPID DIET; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; CHOLESTEROL, DIETARY; DIETARY FATS; FATTY LIVER; HYPERLIPIDEMIAS; OPOSSUMS;

EID: 84863524881     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00008.2012     Document Type: Editorial

References (33)

1. Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in non-alcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 3: 445-451, 2009.
2. Bass NM. Lipidomic dissection of non-alcoholic steatohepatitis: moving beyond foie gras to fat traffic. Hepatology 51: 4-7, 2010.
3. Bieghs V, Wouters K, van Gorp PJ, Gijbels MJJ, De Winther MPJ, Binder CJ, Lütjohann D, Febbraio M, Moore KJ, Van Bilsen M, Hofker MH, Shiri-Sverdlov R. Role of scavenger receptor and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice. Gastroenterology 48: 474-486, 2008.
4. Caballero F, Bataller R, Lacy A, Fernandez-Checa JC, Caballeria J, Garcia-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol 50: 789-796, 2009.
5. Chan J, Sharkey FE, Kushwaha RS, VandeBerg JF, VandeBerg JL. Steatohepatitis in laboratory opossums exhibiting a high lipemic response to dietary cholesterol and fat. Am J Physiol Gastrointest Liver Physiol; doi: 10.1152/ajpgi.00415.2011.
6. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35: 373-379, 2002.
7. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis (NASH): clinical implications. Gastroenterology 142: 711-725, 2012.
8. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845, 1998.
9. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351, 2005.
10. Farrell GC. The liver and the waistline: fifty years of growth. J Gastroenterol Hepatol 24, Suppl 3: 105-118, 2009.
11. Ginsberg HN. Is the slippery slope from steatosis to steatohepatitis paved with triglyceride or cholesterol? Cell Metabolism 4: 179-181, 2006.
12. Han MS, Park SY, Shinzawa K, Kim S, Chung KW, Lee JH, Kwon CH, Lee KW, Lee JH, Park CK, Chung WJ, Hwang JS, Yan JJ, Song DK, Tsujimoto Y, Lee MS. Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res 49: 84-97, 2008.
13. Heydet D, Chen L, Larter C, Inglis C, Silverman M, Farrell G, Leroux M. A truncating mutation of Alms 1 reduces the number of hypothalamic neuronal cilia in obese mice. Dev Neurobiol. In press. doi: 10.1002/ dneu.22031.
14. Kakisaka K, Cazanave SC, Fingas CD, Guicciardi ME, Bronk SF, Werneburg NW, Mott JL, Gores GJ. Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis. Am J Physiol Gastrointest Liver Physiol 302: G77-G84, 2012.
15. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23: 1635-1648, 2008.
16. Larter CZ, Yeh MM, Arsov T, van Rooyen DM, Brooling J, Sheales M, Nolan CJ, Teoh NC, Farrell GC. Steatohepatitis severity in high fat-fed foz/foz mice is dependent on genetic background (Abstract). J Gastroenterol Hepatol 24, Suppl 2: A300, 2009.
17. Larter CZ, Yeh MM, Van Rooyen DM, Teoh NC, Brooling J, Hou JY, Williams J, Clyne M, Nolan CJ, Farrell GC. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice. J Gastroenterol Hepatol 24: 1658-1668, 2009.
18. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. 1. The metabolic movers. J Gastroenterol Hepatol 25: 672-690, 2010.
19. Llacuna L, Fernandez A, Montfort CV, Matías N, Martínez L, Caballero F, Rimola A, Elena M, Morales A, Fernández-Checa JC, García-Ruiz C. Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury. J Hepatol 54: 1002-1010, 2011.
20. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923, 2003.
21. Mari M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, Enrich C, Fernandez-Checa JC, Garcia-Ruiz C. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab 4: 185-198, 2006.
22. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52: 774-788, 2010.
23. Nolan CJ, Larter CZ. Lipotoxicity: why do saturated fatty acids cause and monounsaturates protect against it? J Gastroenterol Hepatol 24: 703-706, 2009.
24. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46: 1081-1090, 2007.
25. Rainwater DL, VandeBerg JL. Dramatic differences in lipoprotein composition among gray short-tailed opossums (Monodelphis domestica) fed a high cholesterol/saturated fat diet. Biochim Biophys Acta 1126: 159-166, 1992.
26. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes non-alcoholic steatohepatitis. Gastroenterology 141: 1393-1403, 2011.
27. van Rooyen DM, Larter CZ, Yeh MM, Haigh GW, Teoh N, Farrell GC. Ezetimibe and artorvastatin ameliorate liver injury in foz/foz mice with NASH (Abstract). J Gastroenterol Hepatol 26, Suppl 4: 2, 2011.
28. Van Rooyen DM, Farrell GC. SREBP-2: a link between insulin resistance, hepatic cholesterol and inflammation in NASH. J Gastroenterol Hepatol 26: 789-792, 2011.
29. Wieckowska A, Zain NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 40: 27-33, 2006.
30. Wiktionary. Play possum (Online). http://en.wiktionary.org/wiki/play_possum [15 Dec. 2011].
31. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140: 124-131, 2011.
32. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48: 474-486, 2008.
33. Wouters K, van Bilsen M, van Gorp PJ, Bieghs V, Lütjohann D, Kerksiek A, Staels B, Hofker MH, Shiri-Sverdlov R. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett 584: 1001-1005, 2010.